Bispecific antibodies: molecules that enable novel therapeutic strategies
- PMID: 17496428
- DOI: 10.1159/000101046
Bispecific antibodies: molecules that enable novel therapeutic strategies
Abstract
Bispecific antibodies are unique in the sense that they can bind simultaneously two different antigens. This property enables the development of therapeutic strategies that are not possible with conventional monoclonal antibodies. The large panel of imaginative bispecific antibody formats that has been developed reflects the strong interest for these molecules. Although in many cases the manufacturing of clinical grade material remains challenging, several bispecific antibody formats are currently in clinical trials.
Copyright (c) 2007 S. Karger AG, Basel.
Comment in
-
Paul Ehrlich no end: antibodies as therapeutic molecules.Pathobiology. 2007;74(1):1-2. doi: 10.1159/000101045. Pathobiology. 2007. PMID: 17496427 No abstract available.
Similar articles
-
Bispecific antibodies for cancer therapy.Immunotherapy. 2009 Mar;1(2):211-22. doi: 10.2217/1750743X.1.2.211. Immunotherapy. 2009. PMID: 20635943 Review.
-
Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer.Curr Opin Mol Ther. 2008 Jun;10(3):273-84. Curr Opin Mol Ther. 2008. PMID: 18535935
-
Diabodies: molecular engineering and therapeutic applications.Drug News Perspect. 2009 Oct;22(8):453-8. Drug News Perspect. 2009. PMID: 20016854 Review.
-
Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.Methods Enzymol. 2012;502:25-41. doi: 10.1016/B978-0-12-416039-2.00002-1. Methods Enzymol. 2012. PMID: 22208980
-
Recombinant bispecific antibodies for cellular cancer immunotherapy.Curr Opin Mol Ther. 2007 Aug;9(4):319-26. Curr Opin Mol Ther. 2007. PMID: 17694444 Review.
Cited by
-
Suppression of MUC1-Overexpressing Tumors by a Novel MUC1/CD3 Bispecific Antibody.Antibodies (Basel). 2023 Jul 13;12(3):47. doi: 10.3390/antib12030047. Antibodies (Basel). 2023. PMID: 37489369 Free PMC article.
-
Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody.Front Immunol. 2023 Apr 4;14:1170042. doi: 10.3389/fimmu.2023.1170042. eCollection 2023. Front Immunol. 2023. PMID: 37081888 Free PMC article.
-
A Generic Strategy to Generate Bifunctional Two-in-One Antibodies by Chicken Immunization.Front Immunol. 2022 Apr 11;13:888838. doi: 10.3389/fimmu.2022.888838. eCollection 2022. Front Immunol. 2022. PMID: 35479092 Free PMC article.
-
Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry.RSC Chem Biol. 2021 Oct 22;3(2):140-169. doi: 10.1039/d1cb00082a. eCollection 2022 Feb 9. RSC Chem Biol. 2021. PMID: 35360884 Free PMC article. Review.
-
Natural immunoglobulin M-based delivery of a complement alternative pathway inhibitor in mouse models of retinal degeneration.Exp Eye Res. 2021 Jun;207:108583. doi: 10.1016/j.exer.2021.108583. Epub 2021 Apr 18. Exp Eye Res. 2021. PMID: 33878326 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
